Physician profile
Eric Tamesis
NPI 1255305132
$9,063.59
in general payments reported to CMS, 2019-2025
45 companies · $1,887 in 2025
The $1,887 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,645 · 2020: $1,263 · 2021: $1,242 · 2022: $1,449 · 2023: $1,254 · 2024: $322 · 2025: $1,887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,463.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,029.57 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $1,749.85 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Janssen Biotech, INC. | $836.73 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Mallinckrodt Hospital Products INC. | $512.88 | 2020-2025 | Acthar |
| Lilly USA, LLC | $394.47 | 2019-2023 | Taltz |
| Pfizer INC. | $393.26 | 2019-2025 | |
| Ucb, INC. | $377.02 | 2019-2025 | Bimzelx, Cimzia |
| Glaxosmithkline, LLC. | $365.77 | 2019-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $264.14 | 2019-2025 | |
| Horizon Therapeutics Plc | $213.48 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $203.52 | 2021-2025 | Saphnelo, Lynparza, Tagrisso |
| Radius Health, INC. | $188.06 | 2019-2025 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $165.27 | 2019-2021 | |
| Genzyme Corporation | $135.08 | 2019-2023 | |
| Genentech USA, INC. | $113.34 | 2019-2025 | Venclexta, Actemra |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $112.14 | 2019 | |
| Aurinia Pharma U.S., INC. | $105.83 | 2021-2025 | Lupkynis |
| Progentec Diagnostics, INC. | $98.00 | 2020 | |
| Ani Pharmaceuticals, INC. | $82.31 | 2023-2025 | Purified Cortrophin Gel |
| Octapharma USA, INC. | $59.56 | 2024-2025 | Octagam Immune Globulin (Human) |
| Daiichi Sankyo INC. | $52.27 | 2024-2025 | Enhertu, Vanflyta |
| Merck Sharp & Dohme LLC | $51.43 | 2025 | Keytruda, Welireg |
| Ibsa Pharma INC. | $48.29 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $45.15 | 2021-2025 | Strensiq, Ultomiris |
| Organon LLC | $44.32 | 2024-2025 | Ontruzant, Hadlima, Renflexis |
| Sobi, INC | $35.01 | 2019 | |
| Pacira Therapeutics, INC. | $32.60 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.89 | 2019-2023 | Cyltezo |
| Mallinckrodt Enterprises LLC | $30.73 | 2019 | |
| Fresenius Kabi USA, LLC | $29.73 | 2023 | Idacio |
| Boston Scientific Corporation | $29.71 | 2025 | Solyx Sis System |
| Invivyd INC | $23.72 | 2025 | Pemgarda |
| Sumitomo Pharma America, INC. | $23.12 | 2024 | Orgovyx |
| Geron Corporation | $22.82 | 2025 | Rytelo |
| Depuy Synthes Sales INC. | $19.81 | 2019 | |
| Servier Pharmaceuticals LLC | $18.30 | 2024 | |
| Sandoz INC. | $16.47 | 2023 | Hyrimoz |
| Organogenesis INC. | $15.93 | 2024 | Puraply Franchise |
| Janssen Scientific Affairs, LLC | $15.64 | 2025 | Tremfya |
| Spectrum Pharmaceuticals INC. | $14.35 | 2025 | Rolvedon |
| Ultragenyx Pharmaceutical INC. | $13.75 | 2020 | |
| Medexus Pharma, INC. | $13.63 | 2019 | |
| Mission Pharmacal Company | $12.28 | 2019 | |
| Zyla Life Sciences, INC. | $11.86 | 2020 | |
| Alvogen INC | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Tamesis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.